menu
    • menu

    Company profile for NiKang Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy ...
    NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in ne

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NiKang TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    NiKang Therapeutics, Inc. 200 Power Mill Road BLDG E400 Wilmington, DE 19803
    Telephone
    Telephone
    (302) 644-5450
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.nikangtx.com/index.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NiKang Unveils First-in-Class Dual Inhibitor NKT5097 at SABCS
    NiKang Unveils First-in-Class Dual Inhibitor NKT5097 at SABCS

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211303516/en/NiKang-Therapeutics-Presents-Discovery-of-NKT5097-a-First-in-Class-Highly-Potent-and-Selective-Orally-Bioavailable-CDK24-Dual-Degrader-for-Cancer-Therapy-at-SABCS-2025

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    NiKang Therapeutics Completes First Phase 1 Dosing of NKT5097
    NiKang Therapeutics Completes First Phase 1 Dosing of NKT5097

    08 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250908965353/en/NiKang-Therapeutics-Completes-Dosing-of-the-First-Cohort-in-a-Phase-1-Study-of-NKT5097-a-First-in-Class-Highly-Potent-and-Selective-Orally-Bioavailable-CDK24-Dual-Degrader

    BUSINESSWIRE
    08 Sep 2025
    Share Share
    NiKang Completes First Cohort Dosing In Ph1 NKT3964 CDK2 Study
    NiKang Completes First Cohort Dosing In Ph1 NKT3964 CDK2 Study

    10 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250310477178/en

    BUSINESSWIRE
    10 Mar 2025
    Share Share
    NiKang Doses First Patient In Ph 1b/2 Of NKT2152 For Liver Cancer
    NiKang Doses First Patient In Ph 1b/2 Of NKT2152 For Liver Cancer

    21 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250121611640/en

    BUSINESSWIRE
    21 Jan 2025
    Share Share
    NiKang Therapeutics Presents NKT3964 PROTAC Degrader For Cancer
    NiKang Therapeutics Presents NKT3964 PROTAC Degrader For Cancer

    24 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024946215/en

    BUSINESSWIRE
    24 Oct 2024
    Share Share
    NiKang To Present NKT2152 Data For Renal Cell Carcinoma At ESMO
    NiKang To Present NKT2152 Data For Renal Cell Carcinoma At ESMO

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240909069810/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search